This clinical trial is focused on patients who have undergone a procedure called catheter ablation to treat atrial fibrillation, a condition that can increase the risk of having a stroke. The study is investigating two different treatments to see which is more effective in reducing the risk of stroke and other related events. The first treatment involves the use of a medication called rivaroxaban, which is a type of blood thinner that helps prevent blood clots. The second treatment uses acetylsalicylic acid, commonly known as aspirin, which is also used to prevent blood clots but works in a different way.

The purpose of the study is to determine whether continuing long-term treatment with rivaroxaban is better than using acetylsalicylic acid alone in preventing strokes and other similar events in patients who are at moderate risk after their successful catheter ablation. Participants in the study will be randomly assigned to receive either rivaroxaban or acetylsalicylic acid. Some participants may receive a placebo, which looks like the real medication but does not contain any active ingredients. The study will last for up to 36 months, during which time participants will have regular check-ups and tests to monitor their health and the effects of the treatment.

The main goal is to see if there is a difference in the occurrence of strokes or other related events between the two treatment groups. The study will also look at other outcomes, such as the occurrence of bleeding, changes in brain scans using MRI, and overall quality of life. This information will help doctors understand the best way to prevent strokes in patients who have had atrial fibrillation and have undergone catheter ablation.